PRESS RELEASE - LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI strategy to enhance discovery on the Axiomer platform, including a partnership with Ginkgo Bioworks and the formation of an AI Advisory Board.